Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$19.86M+41.2%-$33.76M-25.4%-$26.93M-0.7%-$26.73M-11.1%-$24.06M-20.4%
$227K-14.3%$265K+3.5%$256K+1.6%$252K+3.3%$244K-6.2%
$6.96M+22.4%$5.69M+20.2%$4.74M+7.9%$4.39M+8.6%$4.04M+25.9%
-$13.06M+47.1%-$24.7M-41.4%-$17.47M+30.3%-$25.07M-23.9%-$20.24M-40.1%
$86K-49.1%$169K+26.1%$134K+509%$22K-92.4%$291K+28.8%
$37.94M+122%-$174.32M-207%-$56.78M-351%$22.6M+7.4%$21.03M
$531K+70.7%$311K-99.9%$270.53M+429,517%-$63K-1,360%$5K-28.6%
$25.41M+113%-$198.71M-201%$196.29M+7,837%-$2.54M-418%$799K
-$13.15M+47.1%-$24.87M-41.3%-$17.6M+29.9%-$25.09M-22.2%-$20.53M-39.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Rapport Therapeutics, Inc. generate?
Rapport Therapeutics, Inc. (RAPP) generated -$80.3M in operating cash flow over the trailing twelve months.
What is Rapport Therapeutics, Inc.'s free cash flow?
After $411.0K of capital expenditures, Rapport Therapeutics, Inc.'s free cash flow was -$80.7M over the trailing twelve months, down 16.8% year over year.
Where does Rapport Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.